organization · Reporting owner
Lantheus Alpha Therapy, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Perspective Therapeutics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
Jointly reported with Lantheus Holdings, Inc.
Section 16 reporting ended · disclosed 2026-09-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,273,364 |
Last balance in matching sequence
After 2026-09-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-03 · Sale · Disposed 80,783 · Balance 11,440,513 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Row 2 · 2026-09-04 · Sale · Disposed 167,149 · Balance 11,273,364 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 8, 2026 20:51 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | SaleCommon Stock | 167,149 | $3.15 | $526,051.33 |
DisclosureSEC source: 0002064832-26-000318 · form4.xml · nonDerivative · entry 2 Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,273,364 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:51 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | SaleCommon Stock | 80,783 | $3.11 | $250,895.84 |
DisclosureSEC source: 0002064832-26-000318 · form4.xml · nonDerivative · entry 1 Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,440,513 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | SaleCommon Stock | 42,129 | $3.11 | $131,219.20 |
DisclosureSEC source: 0002064832-26-000316 · form4.xml · nonDerivative · entry 1 Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,521,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.025 to $3.235, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 20:58 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | SaleCommon Stock | 35,769 | $3.12 | $111,574.24 |
DisclosureSEC source: 0002064832-26-000314 · form4.xml · nonDerivative · entry 2 Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,563,425 F1 · shares: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · shares: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026. F5 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Read SEC document |
| August 31, 2026 Filed Sep 4, 2026 20:58 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | SaleCommon Stock | 78,145 | $3.14 | $245,609.74 |
DisclosureSEC source: 0002064832-26-000314 · form4.xml · nonDerivative · entry 1 Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,599,194 F1 · shares: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · shares: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · balance_after: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026. F5 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 16:24 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 60,431,039 | $0.95 | $57,409,487.05 |
DisclosureSEC source: 0000950170-24-028446 · ownership.xml · nonDerivative · entry 1 Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,773,394 F1 · kind: Represents securities directly held by Lantheus Alpha Therapy, LLC, ("Lantheus"), a wholly owned direct subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. F1 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC, ("Lantheus"), a wholly owned direct subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.